echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Deteriorating vision for 40 years, patients see the light again, optogenetics, gene therapy, and fast track qualification

    Deteriorating vision for 40 years, patients see the light again, optogenetics, gene therapy, and fast track qualification

    • Last Update: 2021-10-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, GenSight Biologics announced that the US FDA has granted GS030 fast track qualification


    Retinitis pigmentosa is a neurodegenerative eye disease in which patients usually begin to have vision deterioration during childhood


    GS030 combines a single intravitreal injection of gene therapy (GS030-DP) with a wearable photoelectric visual stimulation device (GS030-MD)


    This fast track qualification is based on the positive results of an ongoing Phase 1/2 dose-escalation clinical trial, and aims to evaluate the safety and tolerability of GS030 in 12-18 subjects with advanced retinitis pigmentosa


    Reference materials:

    [1] GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosa.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.